TW202402295A - 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法 - Google Patents

治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法 Download PDF

Info

Publication number
TW202402295A
TW202402295A TW112113060A TW112113060A TW202402295A TW 202402295 A TW202402295 A TW 202402295A TW 112113060 A TW112113060 A TW 112113060A TW 112113060 A TW112113060 A TW 112113060A TW 202402295 A TW202402295 A TW 202402295A
Authority
TW
Taiwan
Prior art keywords
substituted
unsubstituted
cgvhd
patient
inhibitor
Prior art date
Application number
TW112113060A
Other languages
English (en)
Chinese (zh)
Inventor
布魯斯 R 布雷札
萊恩 富林
Original Assignee
美商製藥公司
美國明尼蘇達大學評議委員會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商製藥公司, 美國明尼蘇達大學評議委員會 filed Critical 美商製藥公司
Publication of TW202402295A publication Critical patent/TW202402295A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
TW112113060A 2013-12-02 2014-12-02 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法 TW202402295A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361910944P 2013-12-02 2013-12-02
US61/910,944 2013-12-02
US201461973178P 2014-03-31 2014-03-31
US61/973,178 2014-03-31

Publications (1)

Publication Number Publication Date
TW202402295A true TW202402295A (zh) 2024-01-16

Family

ID=53270044

Family Applications (3)

Application Number Title Priority Date Filing Date
TW112113060A TW202402295A (zh) 2013-12-02 2014-12-02 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
TW110135203A TW202228700A (zh) 2013-12-02 2014-12-02 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
TW103141826A TWI743019B (zh) 2013-12-02 2014-12-02 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110135203A TW202228700A (zh) 2013-12-02 2014-12-02 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
TW103141826A TWI743019B (zh) 2013-12-02 2014-12-02 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法

Country Status (14)

Country Link
US (6) US20150157634A1 (OSRAM)
EP (1) EP3076975A4 (OSRAM)
JP (5) JP2017501140A (OSRAM)
KR (2) KR20230104754A9 (OSRAM)
CN (2) CN105939717B (OSRAM)
AU (4) AU2014360758B2 (OSRAM)
BR (1) BR112016012158A2 (OSRAM)
CA (2) CA3210338A1 (OSRAM)
EA (1) EA201691020A1 (OSRAM)
IL (4) IL292522A (OSRAM)
MX (2) MX389020B (OSRAM)
PH (2) PH12020552048A1 (OSRAM)
TW (3) TW202402295A (OSRAM)
WO (1) WO2015084857A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014030424A8 (pt) 2012-06-04 2017-07-11 Pharmacyclics Inc Formas cristalinas de um inibidor de quinase de tirosina de bruton
KR102452866B1 (ko) * 2013-10-25 2022-10-07 파마싸이클릭스 엘엘씨 이식편 대 숙주 질환의 치료 및 예방 방법
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
WO2017165497A1 (en) * 2016-03-22 2017-09-28 Leof Edward B Using fatty acid synthase inhibitors to treat fibrosis
WO2018002958A1 (en) * 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
WO2018075888A1 (en) * 2016-10-21 2018-04-26 Regents Of The University Of Minnesota Materials and methods for treating or preventing graft-versus-host-disease
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
US12496303B2 (en) 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
WO2022119931A1 (en) * 2020-12-01 2022-06-09 City Of Hope Prevention and treatment of graft-versus-host disease (gvhd)
WO2022161484A1 (en) * 2021-01-30 2022-08-04 Beigene, Ltd. Methods of treating chronic active antibody-mediated rejection using btk inhibitors
US20240287781A1 (en) 2023-02-28 2024-08-29 Toto Ltd. Wall-mounted flush toilet

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US20060182723A1 (en) * 2005-01-25 2006-08-17 Spellberg Brad J Methods for treating refractory infections in neutropenic individuals
EP1981888A4 (en) * 2006-01-13 2010-10-13 Pharmacyclics Inc TYROSINE KINASE INHIBITORS AND USES THEREOF
ES2585902T3 (es) 2006-09-22 2016-10-10 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
CN102159214A (zh) * 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
JP5656976B2 (ja) * 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
CN102666581A (zh) * 2009-08-31 2012-09-12 艾普利穆恩公司 用于抑制移植物排斥的方法和组合物
NZ702485A (en) * 2010-06-03 2016-04-29 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
KR20140058543A (ko) * 2011-07-08 2014-05-14 노파르티스 아게 신규 피롤로 피리미딘 유도체
HK1206624A1 (en) * 2012-04-11 2016-01-15 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
US10722577B2 (en) * 2012-05-25 2020-07-28 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
US8987421B2 (en) * 2013-02-15 2015-03-24 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
KR102452866B1 (ko) * 2013-10-25 2022-10-07 파마싸이클릭스 엘엘씨 이식편 대 숙주 질환의 치료 및 예방 방법
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor

Also Published As

Publication number Publication date
US20250381188A1 (en) 2025-12-18
MX389020B (es) 2025-03-20
CA2932255C (en) 2023-10-10
US20180078558A1 (en) 2018-03-22
PH12016501051A1 (en) 2016-08-15
IL245715A0 (en) 2016-07-31
AU2020204276A1 (en) 2020-07-16
TWI743019B (zh) 2021-10-21
JP2020105181A (ja) 2020-07-09
KR20160085817A (ko) 2016-07-18
MX2016006955A (es) 2016-09-07
CA3210338A1 (en) 2015-06-11
AU2024278490A1 (en) 2025-01-09
US20230100137A1 (en) 2023-03-30
CN110478353A (zh) 2019-11-22
IL276683A (en) 2020-09-30
JP2024072291A (ja) 2024-05-27
US20240293409A1 (en) 2024-09-05
CN105939717B (zh) 2019-09-13
AU2022203810B2 (en) 2024-10-03
WO2015084857A1 (en) 2015-06-11
TW201605454A (zh) 2016-02-16
TW202228700A (zh) 2022-08-01
CN110478353B (zh) 2022-12-30
KR20230104754A9 (ko) 2024-11-15
CA2932255A1 (en) 2015-06-11
JP2017501140A (ja) 2017-01-12
IL292522A (en) 2022-06-01
US20150157634A1 (en) 2015-06-11
EP3076975A1 (en) 2016-10-12
JP2025118595A (ja) 2025-08-13
US20210177854A1 (en) 2021-06-17
EA201691020A1 (ru) 2017-01-30
PH12020552048A1 (en) 2022-05-11
MX2022000209A (es) 2022-02-03
AU2022203810A1 (en) 2022-06-23
AU2014360758B2 (en) 2020-03-26
BR112016012158A2 (pt) 2017-09-26
KR20230104754A (ko) 2023-07-10
AU2014360758A1 (en) 2016-06-16
JP2023029899A (ja) 2023-03-07
IL315228A (en) 2024-10-01
CN105939717A (zh) 2016-09-14
EP3076975A4 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
US20240293409A1 (en) Methods of treating and preventing alloantibody driven chronic graft versus host disease
AU2022202686B2 (en) Methods of treating and preventing graft versus host disease
HK40031991B (zh) 治疗和预防移植物抗宿主病的方法
HK40086449A (en) Methods of treating and preventing graft versus host disease
EA045869B1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"